Pharmacokinetics of LY2409021 Following Administration to Subjects With Varying Degrees of Renal Function
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 09 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 20 Mar 2014 Planned End Date changed from 1 Aug 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.